122 related articles for article (PubMed ID: 15451528)
21. Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives.
Mundargi RC; Babu VR; Rangaswamy V; Patel P; Aminabhavi TM
J Control Release; 2008 Feb; 125(3):193-209. PubMed ID: 18083265
[TBL] [Abstract][Full Text] [Related]
22. Poly(lactide-co-glycolide) microparticles as systems for controlled release of proteins -- preparation and characterization.
Porjazoska A; Goracinova K; Mladenovska K; Glavas M; Simonovska M; Janjević EI; Cvetkovska M
Acta Pharm; 2004 Sep; 54(3):215-29. PubMed ID: 15610618
[TBL] [Abstract][Full Text] [Related]
23. A potential approach for decreasing the burst effect of protein from PLGA microspheres.
Fu K; Harrell R; Zinski K; Um C; Jaklenec A; Frazier J; Lotan N; Burke P; Klibanov AM; Langer R
J Pharm Sci; 2003 Aug; 92(8):1582-91. PubMed ID: 12884245
[TBL] [Abstract][Full Text] [Related]
24. Biodistribution properties of nanoparticles based on mixtures of PLGA with PLGA-PEG diblock copolymers.
Beletsi A; Panagi Z; Avgoustakis K
Int J Pharm; 2005 Jul; 298(1):233-41. PubMed ID: 15936907
[TBL] [Abstract][Full Text] [Related]
25. Poly(vinyl alcohol)-graft-poly(lactide-co-glycolide) nanoparticles for local delivery of paclitaxel for restenosis treatment.
Westedt U; Kalinowski M; Wittmar M; Merdan T; Unger F; Fuchs J; Schäller S; Bakowsky U; Kissel T
J Control Release; 2007 May; 119(1):41-51. PubMed ID: 17346845
[TBL] [Abstract][Full Text] [Related]
26. The intracellular uptake ability of chitosan-coated Poly (D,L-lactide-co-glycolide) nanoparticles.
Kim BS; Kim CS; Lee KM
Arch Pharm Res; 2008 Aug; 31(8):1050-4. PubMed ID: 18787796
[TBL] [Abstract][Full Text] [Related]
27. Properties of poly(lactic-co-glycolic acid) nanospheres containing protease inhibitors: camostat mesilate and nafamostat mesilate.
Yin J; Noda Y; Yotsuyanagi T
Int J Pharm; 2006 May; 314(1):46-55. PubMed ID: 16551494
[TBL] [Abstract][Full Text] [Related]
28. Improved bioavailability of orally administered mifepristone from PLGA nanoparticles.
He W; Horn SW; Hussain MD
Int J Pharm; 2007 Apr; 334(1-2):173-8. PubMed ID: 17101249
[TBL] [Abstract][Full Text] [Related]
29. Factorial design, physicochemical characterisation and activity of ciprofloxacin-PLGA nanoparticles.
Dillen K; Vandervoort J; Van den Mooter G; Verheyden L; Ludwig A
Int J Pharm; 2004 May; 275(1-2):171-87. PubMed ID: 15081148
[TBL] [Abstract][Full Text] [Related]
30. Enhanced surface attachment of protein-type targeting ligands to poly(lactide-co-glycolide) nanoparticles using variable expression of polymeric acid functionality.
McCarron PA; Marouf WM; Donnelly RF; Scott C
J Biomed Mater Res A; 2008 Dec; 87(4):873-84. PubMed ID: 18228271
[TBL] [Abstract][Full Text] [Related]
31. Fabrication and characterization of PLGA/HAp composite scaffolds for delivery of BMP-2 plasmid DNA.
Nie H; Wang CH
J Control Release; 2007 Jul; 120(1-2):111-21. PubMed ID: 17512077
[TBL] [Abstract][Full Text] [Related]
32. Preparation and characterization of PLGA particles for subcutaneous controlled drug release by membrane emulsification.
Gasparini G; Kosvintsev SR; Stillwell MT; Holdich RG
Colloids Surf B Biointerfaces; 2008 Feb; 61(2):199-207. PubMed ID: 17919891
[TBL] [Abstract][Full Text] [Related]
33. Radiosensitization of paclitaxel, etanidazole and paclitaxel+etanidazole nanoparticles on hypoxic human tumor cells in vitro.
Jin C; Bai L; Wu H; Tian F; Guo G
Biomaterials; 2007 Sep; 28(25):3724-30. PubMed ID: 17509678
[TBL] [Abstract][Full Text] [Related]
34. Development and characterization of PLGA nanospheres and nanocapsules containing xanthone and 3-methoxyxanthone.
Teixeira M; Alonso MJ; Pinto MM; Barbosa CM
Eur J Pharm Biopharm; 2005 Apr; 59(3):491-500. PubMed ID: 15760730
[TBL] [Abstract][Full Text] [Related]
35. Sustained release of dexamethasone from hydrophilic matrices using PLGA nanoparticles for neural drug delivery.
Kim DH; Martin DC
Biomaterials; 2006 May; 27(15):3031-7. PubMed ID: 16443270
[TBL] [Abstract][Full Text] [Related]
36. Novel one-pot facile technique for preparing nanoparticles modified with hydrophilic polymers on the surface via block polymer-assisted emulsification/evaporation process.
Kanakubo Y; Ito F; Murakami Y
Colloids Surf B Biointerfaces; 2010 Jun; 78(1):85-91. PubMed ID: 20223642
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics and tissue distribution studies of orally administered nanoparticles encapsulated ethionamide used as potential drug delivery system in management of multi-drug resistant tuberculosis.
Kumar G; Sharma S; Shafiq N; Pandhi P; Khuller GK; Malhotra S
Drug Deliv; 2011 Jan; 18(1):65-73. PubMed ID: 20735202
[TBL] [Abstract][Full Text] [Related]
38. Poly(d,l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs.
Dong Y; Feng SS
Biomaterials; 2005 Oct; 26(30):6068-76. PubMed ID: 15894372
[TBL] [Abstract][Full Text] [Related]
39. Development of a novel formulation containing poly(d,l-lactide-co-glycolide) microspheres dispersed in PLGA-PEG-PLGA gel for sustained delivery of ganciclovir.
Duvvuri S; Janoria KG; Mitra AK
J Control Release; 2005 Nov; 108(2-3):282-93. PubMed ID: 16229919
[TBL] [Abstract][Full Text] [Related]
40. Solid-state solubility influences encapsulation and release of hydrophobic drugs from PLGA/PLA nanoparticles.
Panyam J; Williams D; Dash A; Leslie-Pelecky D; Labhasetwar V
J Pharm Sci; 2004 Jul; 93(7):1804-14. PubMed ID: 15176068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
